Safety and Efficacy Study of a Eye Drop for Eye Allergy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vistakon Pharmaceuticals
• Treatments: Alcaftadine; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• At least 10 years of age

• positive history of ocular allergies

• positive skin test reaction to allergens.

Exclusion Criteria:

• known allergy, contraindication, or sensitivities to the use of any of the study medication(s) or their components

• ocular surgical intervention within three (3) months prior to visit 1 or during the study

• known history of retinal detachment, diabetic retinopathy, or progressive retinal disease, or glaucoma

• any other significant illness